As an afterthought, how much we can expect to profit depends really on what premium an acquiring company is willing to pay for what we think is a valuable company. If the deal were offered today at the closing price of 6.56/share, then a 300% premium would translate into 19.68/share. An 800% premium translates into 52.48/share, and so on, you do the math. This company has been struggling for over 20 years and we are just seeing a glimmer of light at the end of that long dark tunnel. If that light is not extinguished by the anticipated data and everything turns out the way management has hoped for, then selling out to a large pharma will not produce the humongous returns from our investments we have all been expecting which, in my opinion, can only be realized by management proclaiming they will go forward alone with research, production and sales, with perhaps a joint venture with an established pharma.
Your aspirations appear quite modest for a company supposedly on the verge of completing blockbuster drug protocols. I do admire you for being satisfied with only a sports car and good dinner, items you probably already can afford without speculating on the eventual outcome of this investment. Anyway, good luck to all!